Johnson & Johnson
Recent News About Johnson & Johnson
-
FDA approves CAPLYTA as adjunctive therapy for major depressive disorder in adults
Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) has approved CAPLYTA (lumateperone) as an adjunctive therapy with antidepressants for adults with major depressive disorder (MDD).
-
Johnson & Johnson to present at Citi’s 2025 Global Healthcare Conference
Johnson & Johnson announced that it will take part in Citi’s 2025 Global Healthcare Conference, scheduled for December 3, 2025.
-
Johnson & Johnson reports positive one-year data on Shockwave Javelin catheter for peripheral artery disease
Johnson & Johnson MedTech has announced new one-year data on its Shockwave Javelin Peripheral IVL Catheter, presented at the Vascular InterVentional Advances (VIVA) 2025 conference in Las Vegas.
-
Johnson & Johnson MedTech reports positive one-year results for Shockwave IVL system
Johnson & Johnson MedTech presented new one-year results from the DISRUPT BTK II study at the Vascular InterVentional Advances (VIVA) 2025 meeting in Las Vegas.
-
Johnson & Johnson MedTech presents new data on cardiac arrhythmia treatments at APHRS/JHRS
Johnson & Johnson MedTech has announced that new clinical and real-world data from its VARIPULSE Platform, used in pulsed field ablation (PFA) procedures for atrial fibrillation (AF), will be presented at the upcoming Asia Pacific Heart Rhythm...
-
Johnson & Johnson seeks FDA expansion for STELARA use in young children with ulcerative colitis
Johnson & Johnson has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) to seek expanded approval of STELARA (ustekinumab) for treating children aged two years and older with moderately to...
-
Johnson & Johnson MedTech advances surgical robotics with AI-driven simulation
Johnson & Johnson MedTech has announced new advancements in the development of its robotics systems, using artificial intelligence (AI) technologies to create simulated environments aimed at speeding up product innovation, optimizing clinical...
-
Johnson & Johnson awards Mayo Clinic and QAS.AI in first round of surgical AI innovation fund
Johnson & Johnson MedTech has announced the advancement of its Polyphonic AI Fund for Surgery, an initiative aimed at accelerating artificial intelligence (AI) solutions to improve surgical care.
-
Johnson & Johnson reports positive mid-stage trial results for icotrokinra in ulcerative colitis
Johnson & Johnson has released new results from its Phase 2b ANTHEM-UC study, showing that icotrokinra, an investigational oral peptide targeting the IL-23 receptor, maintained both therapeutic benefit and a favorable safety profile through 28...
-
Johnson & Johnson study highlights unmet needs in psoriasis care and preference for oral treatments
Johnson & Johnson has announced new findings from the U.S. segment of the global ENCOMPASS study, which evaluated both patient and healthcare provider perspectives on challenges and unmet needs in psoriasis care.
-
Johnson & Johnson MedTech presents new Impella data at TCT 2025
Johnson & Johnson MedTech will present new data and innovations related to its Impella heart pump at the Transcatheter Cardiovascular Therapeutics (TCT) conference, scheduled for October 25–28 in San Francisco.
-
Johnson & Johnson reports positive phase 2 results for nipocalimab in Sjögren’s disease
Johnson & Johnson has announced results from the Phase 2 DAHLIAS study, published in The Lancet, indicating that nipocalimab, an investigational FcRn inhibitor, significantly reduced disease activity and severity in patients with...
-
Johnson & Johnson reports positive long-term results for oral peptide icotrokinra in plaque psoriasis
Johnson & Johnson has released new long-term data from its Phase 3 ICONIC-TOTAL study, evaluating the investigational oral peptide icotrokinra in adults and adolescents with plaque psoriasis affecting challenging areas such as the scalp, genitals,...
-
Johnson & Johnson to join Wolfe Research Healthcare Conference with webcast on November 17
Johnson & Johnson has announced that it will participate in the 7th Annual Wolfe Research Healthcare Conference, scheduled for Monday, November 17, 2025.
-
Johnson & Johnson reports positive early results from SunRISe-4 bladder cancer study
Johnson & Johnson announced results from the primary analysis of its ongoing Phase 2b SunRISe-4 study, which evaluated the combination of INLEXZO (gemcitabine intravesical system) and intravenous cetrelimab in patients with muscle invasive bladder...
-
Johnson & Johnson receives FDA Priority Review for AKEEGA in BRCA-mutated prostate cancer
Johnson & Johnson has announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review for its supplemental New Drug Application (sNDA) for AKEEGA (niraparib and abiraterone acetate dual-action tablet) combined with...
-
Johnson & Johnson to present new data on solid tumor therapies at ESMO 2025
Johnson & Johnson announced it will present 16 studies at the European Society for Medical Oncology (ESMO) 2025 Congress, focusing on progress in treatments for solid tumors such as head and neck, lung, bladder, and prostate cancers.
-
Johnson & Johnson posts higher Q3 profit and lifts full-year outlook
Johnson & Johnson has reported its financial results for the third quarter of 2025, showing an increase in both sales and net earnings compared to the same period last year.
-
Johnson & Johnson declares $1.30 quarterly dividend for fourth quarter of 2025
Johnson & Johnson has announced that its Board of Directors has declared a cash dividend for the fourth quarter of 2025.
-
Johnson & Johnson plans spin-off of orthopaedics unit as standalone DePuy Synthes
Johnson & Johnson has announced plans to separate its Orthopaedics business, aiming to enhance strategic and operational focus for both the parent company and the new entity.